ARCT
Price
$11.19
Change
-$0.19 (-1.67%)
Updated
May 9, 12:15 PM (EDT)
Capitalization
296.96M
3 days until earnings call
RCKT
Price
$6.93
Change
-$0.11 (-1.56%)
Updated
May 9, 02:04 PM (EDT)
Capitalization
715.46M
94 days until earnings call
Ad is loading...

ARCT vs RCKT

Header iconARCT vs RCKT Comparison
Open Charts ARCT vs RCKTBanner chart's image
Arcturus Therapeutics Holdings
Price$11.19
Change-$0.19 (-1.67%)
Volume$300
Capitalization296.96M
Rocket Pharmaceuticals
Price$6.93
Change-$0.11 (-1.56%)
Volume$1.67K
Capitalization715.46M
ARCT vs RCKT Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. RCKT commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and RCKT is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (ARCT: $11.38 vs. RCKT: $7.04)
Brand notoriety: ARCT and RCKT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 88% vs. RCKT: 93%
Market capitalization -- ARCT: $296.96M vs. RCKT: $715.46M
ARCT [@Biotechnology] is valued at $296.96M. RCKT’s [@Biotechnology] market capitalization is $715.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileRCKT’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • RCKT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARCT and RCKT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 3 TA indicator(s) are bullish while RCKT’s TA Score has 5 bullish TA indicator(s).

  • ARCT’s TA Score: 3 bullish, 6 bearish.
  • RCKT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCKT is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -8.96% price change this week, while RCKT (@Biotechnology) price change was -10.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.07%. For the same industry, the average monthly price growth was +11.11%, and the average quarterly price growth was -13.36%.

Reported Earning Dates

ARCT is expected to report earnings on May 12, 2025.

RCKT is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (-5.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCKT($715M) has a higher market cap than ARCT($297M). ARCT YTD gains are higher at: -32.940 vs. RCKT (-43.994). ARCT has higher annual earnings (EBITDA): -77.4M vs. RCKT (-247.48M). RCKT has more cash in the bank: 372M vs. ARCT (237M). RCKT has less debt than ARCT: RCKT (25.5M) vs ARCT (28.6M). ARCT has higher revenues than RCKT: ARCT (138M) vs RCKT (0).
ARCTRCKTARCT / RCKT
Capitalization297M715M42%
EBITDA-77.4M-247.48M31%
Gain YTD-32.940-43.99475%
P/E RatioN/AN/A-
Revenue138M0-
Total Cash237M372M64%
Total Debt28.6M25.5M112%
FUNDAMENTALS RATINGS
ARCT vs RCKT: Fundamental Ratings
ARCT
RCKT
OUTLOOK RATING
1..100
1518
VALUATION
overvalued / fair valued / undervalued
1..100
49
Fair valued
28
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9193
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RCKT's Valuation (28) in the Biotechnology industry is in the same range as ARCT (49) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to ARCT’s over the last 12 months.

RCKT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that RCKT’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as RCKT (93) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RCKT’s over the last 12 months.

ARCT's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as RCKT (64) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RCKT’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as RCKT (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to RCKT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTRCKT
RSI
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
73%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 4 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
76%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCKT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NEQCX11.41N/A
N/A
Neuberger Berman U.S. Equity Impact C
PHSRX48.96N/A
N/A
Putnam Global Health Care R
OAKBX35.50N/A
N/A
Oakmark Equity And Income Investor
HSMSX11.71N/A
N/A
Hartford Small Cap Value R4
HLMVX34.21N/A
N/A
Harding Loevner Global Equity Inst

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with BMEA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+3.93%
BMEA - ARCT
52%
Loosely correlated
+2.94%
ABCL - ARCT
49%
Loosely correlated
N/A
TRDA - ARCT
49%
Loosely correlated
+5.64%
AXON - ARCT
49%
Loosely correlated
+14.13%
RCKT - ARCT
44%
Loosely correlated
+11.57%
More